SCHEDULE: Farallon Capital Management Discloses 9.9% Stake in Agios Pharmaceuticals

Farallon Capital Management, L.L.C. and its affiliates have reported beneficial ownership of 5,917,400 shares, representing 9.9% of the outstanding common stock of Agios Pharmaceuticals, Inc.

Summary

• Farallon Capital Management, L.L.C. and its affiliated entities have filed a Schedule 13G, indicating their beneficial ownership of 5,917,400 shares of Agios Pharmaceuticals, Inc. common stock.
• This holding represents 9.9% of the total outstanding shares of Agios Pharmaceuticals, Inc.
• The filing is an amendment (Amendment No. 5) and the event date requiring the filing is June 30, 2026.
• The reporting persons are Farallon Capital Management, L.L.C. (the Investment Manager) and several associated investment partnerships and individuals.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it is a routine Schedule 13G filing indicating a significant ownership stake but not necessarily a change in investment strategy or a strong opinion on the company's future.

Positives

• Farallon Capital Management's significant stake (9.9%) suggests a strong conviction in Agios Pharmaceuticals' long-term value.
• The filing indicates that the shares were acquired and are held in the ordinary course of business, not for the purpose of influencing control.

Negatives

• The filing does not provide specific financial performance data for Agios Pharmaceuticals, as it is a Schedule 13G disclosure by an investor, not an issuer report.

Risks

• As a Schedule 13G filing, it primarily reports ownership and does not detail specific risks related to Agios Pharmaceuticals' business operations or future prospects.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Agios Pharmaceuticals.

Management Comments

• The filing includes a certification stating that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that significant stakes reported in Schedule 13G filings by investment firms like Farallon Capital Management often signal active investment strategies within the biotechnology and pharmaceutical sectors, where such firms frequently seek undervalued or growth-oriented companies.

Stakeholder Impact

• Shareholders of Agios Pharmaceuticals may view the significant stake held by Farallon Capital Management as a positive indicator of institutional confidence, potentially influencing market perception.
• Other investors may monitor Farallon's activities for potential future trading patterns.

Next Steps

• Farallon Capital Management will continue to hold its stake in Agios Pharmaceuticals, Inc.
• Future amendments to this Schedule 13G will be filed if there are changes in beneficial ownership.

Key Dates

Keywords

Agios Pharmaceuticals, Farallon Capital Management, Schedule 13G, Beneficial Ownership, Investment Management, Common Stock, Ownership Stake